Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume 54, Issue -, Pages 51-61Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2020.06.013
Keywords
SARS-CoV-2; COVID-19; JAK/STAT pathway; Ruxolitinib; Cytokine storm
Categories
Ask authors/readers for more resources
Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response. This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuses on the potential efficacy of ruxolitinib in this infection. The potential targets of ruxolitinib were determined by using genetic alterations that have been reported in COVID-19 patients. The potential effectiveness of ruxolitinib is suggested by evaluating the interactions of these potential targets with ruxolitinib or JAK/STAT pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available